aspirin has been researched along with Indigestion in 72 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the impact of prophylactic omeprazole with background dual anti-platelet therapy on patient-reported symptoms of dyspepsia compared to placebo." | 9.20 | The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; McIntosh, AI; Schnitzer, TJ; Vardi, M, 2015) |
| "To evaluate the risk of gastrointestinal (GI) symptoms and ulcers associated to the use of low-dose aspirin (ASA) among patients with rheumatoid arthritis (RA) and osteoarthritis (OA) treated with cyclooxygenase-2 (COX-2) drugs, to clarify the controversy in the literature." | 9.12 | The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors. ( Benito-Garcia, E; Michaud, K; Wolfe, F, 2007) |
| "Failure to increase sensory thresholds during treatment with aspirin is associated with the development of dyspepsia." | 9.10 | Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin? ( Buenger, L; Gerken, G; Gschossmann, J; Holtmann, G; Talley, NJ, 2002) |
| "Doses of 600 mg and 1200 mg of D(-)penicillamine daily were superior to a standard regimen of therapy in rheumatoid arthritis." | 9.04 | Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen. ( Davies, J; Dixon, AJ; Dormandy, TL; Hamilton, EB; Holt, PJ; Mason, RM; Thompson, M; Weber, JC; Zutshi, DW, 1975) |
| "To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness." | 8.88 | Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 8.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| "This pooled analysis demonstrates a clear decrease in dyspepsia and an improvement in upper gastrointestinal tolerability for patients with osteoarthritis and rheumatoid arthritis taking valdecoxib, even at supratherapeutic doses, compared with those taking nonspecific nonsteroidal anti-inflammatory drugs over 12 weeks." | 8.82 | Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. ( Eisen, GM; Goldstein, JL; Hanna, DB; Rublee, DA, 2005) |
| "Non-steroidal anti-inflammatory drug and aspirin (here collectively called NSAIDs) use is the second most common aetiologic factor for peptic ulcer disease and a major factor for peptic ulcer complications." | 7.71 | Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. ( Färkkilä, M; Juhola, M; Mäntynen, T; Sipponen, P; Voutilainen, M, 2001) |
| "Dyspepsia in the community is linked to smoking and aspirin use, but not to H pylori infection." | 7.70 | Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. ( Hazel, S; Jones, M; Mitchell, H; Nandurkar, S; Talley, NJ; Xia, H, 1998) |
| "To assess the impact of prophylactic omeprazole with background dual anti-platelet therapy on patient-reported symptoms of dyspepsia compared to placebo." | 5.20 | The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; McIntosh, AI; Schnitzer, TJ; Vardi, M, 2015) |
| "To evaluate the risk of gastrointestinal (GI) symptoms and ulcers associated to the use of low-dose aspirin (ASA) among patients with rheumatoid arthritis (RA) and osteoarthritis (OA) treated with cyclooxygenase-2 (COX-2) drugs, to clarify the controversy in the literature." | 5.12 | The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors. ( Benito-Garcia, E; Michaud, K; Wolfe, F, 2007) |
| "Failure to increase sensory thresholds during treatment with aspirin is associated with the development of dyspepsia." | 5.10 | Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin? ( Buenger, L; Gerken, G; Gschossmann, J; Holtmann, G; Talley, NJ, 2002) |
| "Doses of 600 mg and 1200 mg of D(-)penicillamine daily were superior to a standard regimen of therapy in rheumatoid arthritis." | 5.04 | Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen. ( Davies, J; Dixon, AJ; Dormandy, TL; Hamilton, EB; Holt, PJ; Mason, RM; Thompson, M; Weber, JC; Zutshi, DW, 1975) |
| "To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness." | 4.88 | Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 4.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| "This pooled analysis demonstrates a clear decrease in dyspepsia and an improvement in upper gastrointestinal tolerability for patients with osteoarthritis and rheumatoid arthritis taking valdecoxib, even at supratherapeutic doses, compared with those taking nonspecific nonsteroidal anti-inflammatory drugs over 12 weeks." | 4.82 | Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. ( Eisen, GM; Goldstein, JL; Hanna, DB; Rublee, DA, 2005) |
| "A total of 40 patients with functional dyspepsia (20 with Helicobacter pylori-negative chronic gastritis, and 20 with Helicobacter pylori-positive chronic gastritis), and 37 Helicobacter pylori-negative long-term non-steroidal anti-inflammatory drug users (26 with aspirin, 11 with selective cyclooxygenase-2 inhibitors) were selected." | 3.78 | Helicobacter pylori infection and administration of non-steroidal anti-inflammatory drugs down-regulate the expression of gastrokine-1 in gastric mucosa. ( Chen, J; Chen, LZ; Chen, MH; Mao, W; Peng, TL; Yin, XF, 2012) |
| "Non-steroidal anti-inflammatory drug and aspirin (here collectively called NSAIDs) use is the second most common aetiologic factor for peptic ulcer disease and a major factor for peptic ulcer complications." | 3.71 | Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. ( Färkkilä, M; Juhola, M; Mäntynen, T; Sipponen, P; Voutilainen, M, 2001) |
| "Assuming the difference in the use of medication for dyspepsia between patients and controls was due to aspirin, the full cost of aspirin treatment was 4." | 3.71 | Costs of aspirin and statins in general practice. ( Drummond, A; Durrington, PN; Kwok, S; Morgan, J, 2002) |
| "Dyspepsia in the community is linked to smoking and aspirin use, but not to H pylori infection." | 3.70 | Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. ( Hazel, S; Jones, M; Mitchell, H; Nandurkar, S; Talley, NJ; Xia, H, 1998) |
| "Smoking, alcohol, aspirin, non-aspirin NSAIDs, and acetaminophen were not associated with functional dyspepsia." | 3.69 | Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups. ( Talley, NJ; Weaver, AL; Zinsmeister, AR, 1994) |
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| "60." | 2.79 | Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. ( Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E, 2014) |
| "Although low-dose acetylsalicylic acid (ASA) is recommended for prevention of cardiovascular events in at-risk patients, its long-term use can be associated with the risk of peptic ulcer and upper gastrointestinal (GI) symptoms that may impact treatment compliance." | 2.78 | Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. ( Agewall, S; Herlitz, J; Lanas, A; Nagy, P; Nauclér, EC; Scheiman, JM; Svedberg, LE; Veldhuyzen van Zanten, SJ, 2013) |
| "Most people who experience migraine use OTC medications to treat their symptoms, but no head-to-head clinical trials comparing these agents with prescription migraine therapies have been published." | 2.71 | Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. ( Baggish, J; Battikha, JP; Elkind, AH; Gallagher, RM; Goldstein, J; Hoffman, H; Saper, JR; Silberstein, SD; Smith, TR, 2005) |
| "Dyspepsia is prevalent in the Rwandan setting and is associated with a significant burden on quality of life." | 1.56 | Prevalence and sociodemographic determinants of dyspepsia in the general population of Rwanda. ( Bangamwabo, JB; Chetwood, JD; Dusabejambo, V; Jones, M; Kieffer, KA; Nkurunziza, A; Ntirenganya, C; Nuki, G; Walker, TD, 2020) |
| "Dyspepsia is a common problem in the community and clinical practice with symptom(s) considered arising from the gastroduodenal region." | 1.48 | Uninvestigated dyspepsia and associated factors of patients with gastrointestinal disorders in Dessie Referral Hospital, Northeast Ethiopia. ( Demsiss, W; Seid, A; Tamir, Z, 2018) |
| "Uninvestigated dyspepsia is common in family practice." | 1.32 | The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. ( Armstrong, D; Barkun, AN; Chakraborty, B; Chiba, N; Daniels, S; Escobedo, S; Sinclair, P; Thomson, AB; Van Zanten, SJ; White, RJ, 2003) |
| "Aspirin was associated with dyspepsia and/or heartburn (OR = 1." | 1.29 | Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. ( Evans, JM; Fleming, KC; Harmsen, WS; Melton, LJ; Talley, NJ; Zinsmeister, AR, 1995) |
| "Gastroduodenal ulcers were found in 94 (44%) of the patients; two thirds of the users and one third of the non-users." | 1.29 | [Use of acetylsalicylic acid and other antiphlogistics in hematemesis/melena]. ( Aabakken, L; Breckan, RK, 1994) |
| "Dyspepsia is common in the general population, and despite a paucity of data, smoking, alcohol, and analgesics are believed to be important risk factors." | 1.29 | Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups: lack of an association in a community. ( Melton, LJ; Schleck, CD; Talley, NJ; Zinsmeister, AR, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (31.94) | 18.7374 |
| 1990's | 8 (11.11) | 18.2507 |
| 2000's | 30 (41.67) | 29.6817 |
| 2010's | 10 (13.89) | 24.3611 |
| 2020's | 1 (1.39) | 2.80 |
| Authors | Studies |
|---|---|
| Bangamwabo, JB | 1 |
| Chetwood, JD | 1 |
| Dusabejambo, V | 1 |
| Ntirenganya, C | 1 |
| Nuki, G | 1 |
| Nkurunziza, A | 1 |
| Kieffer, KA | 1 |
| Jones, M | 2 |
| Walker, TD | 1 |
| Seid, A | 1 |
| Tamir, Z | 1 |
| Demsiss, W | 1 |
| Alvarez-Sabín, J | 1 |
| Quintana, M | 1 |
| Santamarina, E | 1 |
| Maisterra, O | 1 |
| Haastrup, P | 1 |
| Jarbøl, DE | 1 |
| Vardi, M | 1 |
| Cryer, BL | 2 |
| Cohen, M | 2 |
| Lanas, A | 7 |
| Schnitzer, TJ | 2 |
| Lapuerta, P | 2 |
| Goldsmith, MA | 2 |
| Laine, L | 3 |
| Doros, G | 2 |
| Liu, Y | 2 |
| McIntosh, AI | 1 |
| Cannon, CP | 2 |
| Bhatt, DL | 2 |
| Vaduganathan, M | 1 |
| Hsieh, WH | 1 |
| Shook, TL | 1 |
| van Oijen, MG | 1 |
| Focks, JJ | 1 |
| Laheij, RJ | 2 |
| KAY, J | 1 |
| McCarthy, D | 1 |
| Voelker, M | 1 |
| Brueckner, A | 1 |
| Senn, S | 1 |
| Baron, JA | 1 |
| McCarthy, DM | 1 |
| Mao, W | 1 |
| Chen, J | 1 |
| Peng, TL | 1 |
| Yin, XF | 1 |
| Chen, LZ | 1 |
| Chen, MH | 1 |
| Scheiman, JM | 3 |
| Herlitz, J | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Agewall, S | 1 |
| Nauclér, EC | 1 |
| Svedberg, LE | 1 |
| Nagy, P | 1 |
| Deeks, JJ | 1 |
| Holtmann, G | 2 |
| Gschossmann, J | 1 |
| Buenger, L | 1 |
| Gerken, G | 1 |
| Talley, NJ | 8 |
| Thomson, AB | 1 |
| Barkun, AN | 1 |
| Armstrong, D | 1 |
| Chiba, N | 1 |
| White, RJ | 1 |
| Daniels, S | 1 |
| Escobedo, S | 1 |
| Chakraborty, B | 1 |
| Sinclair, P | 1 |
| Van Zanten, SJ | 1 |
| Thiéfin, G | 1 |
| Westerlund, T | 1 |
| Allebeck, P | 1 |
| Marklund, B | 1 |
| Andersson, IL | 1 |
| Brånstad, JO | 1 |
| Sjöblom, M | 1 |
| VIGUIE, R | 1 |
| GARDIES, AL | 1 |
| Füessl, HS | 1 |
| Treiber, G | 1 |
| Schwabe, M | 1 |
| Ammon, S | 1 |
| Walker, S | 1 |
| Klotz, U | 1 |
| Malfertheiner, P | 1 |
| Jones, L | 1 |
| Griffin, S | 1 |
| Palmer, S | 1 |
| Main, C | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Sudlow, C | 1 |
| Henderson, R | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Eisen, GM | 1 |
| Goldstein, JL | 1 |
| Hanna, DB | 1 |
| Rublee, DA | 1 |
| Bazzoli, F | 1 |
| Goldstein, J | 1 |
| Silberstein, SD | 1 |
| Saper, JR | 1 |
| Elkind, AH | 1 |
| Smith, TR | 1 |
| Gallagher, RM | 1 |
| Battikha, JP | 1 |
| Hoffman, H | 1 |
| Baggish, J | 1 |
| Vogt, W | 1 |
| Taylor, KM | 1 |
| Harris, AW | 1 |
| Ji, KY | 1 |
| Hu, FL | 1 |
| Ferrandez, A | 1 |
| Stiefelhagen, P | 1 |
| Ford, AC | 1 |
| Forman, D | 1 |
| Bailey, AG | 1 |
| Axon, AT | 1 |
| Moayyedi, P | 1 |
| Benito-Garcia, E | 1 |
| Michaud, K | 1 |
| Wolfe, F | 1 |
| Tuteja, AK | 1 |
| Joos, SK | 1 |
| Tolman, KG | 1 |
| Hickam, DH | 1 |
| Tseng, GY | 1 |
| Lin, HJ | 1 |
| Visconti, G | 1 |
| Spotti, D | 1 |
| Piperno, A | 1 |
| Marini, U | 1 |
| Evans, JM | 1 |
| Fleming, KC | 1 |
| Harmsen, WS | 1 |
| Zinsmeister, AR | 3 |
| Melton, LJ | 2 |
| Weaver, AL | 1 |
| Goebell, H | 1 |
| Holtmann, M | 1 |
| Breckan, RK | 1 |
| Aabakken, L | 1 |
| Schleck, CD | 1 |
| Mansfield, JC | 1 |
| Greenaway, JR | 1 |
| Contractor, BR | 1 |
| Idle, N | 1 |
| Bramble, MG | 1 |
| Nandurkar, S | 1 |
| Xia, H | 1 |
| Mitchell, H | 1 |
| Hazel, S | 1 |
| Cleland, JG | 1 |
| Alamgir, F | 1 |
| Hawkey, CJ | 2 |
| Lanas, AI | 1 |
| Jansen, JB | 1 |
| Verbeek, AL | 1 |
| Verheugt, FW | 1 |
| Voutilainen, M | 1 |
| Mäntynen, T | 1 |
| Färkkilä, M | 1 |
| Juhola, M | 1 |
| Sipponen, P | 1 |
| Drummond, A | 1 |
| Kwok, S | 1 |
| Morgan, J | 1 |
| Durrington, PN | 1 |
| Oddsson, E | 1 |
| Binder, V | 1 |
| Thorgeirsson, T | 1 |
| Jonasson, TA | 1 |
| Gunnlaugsson, O | 1 |
| Wulff, M | 1 |
| Jónasson, K | 1 |
| Wulff, HR | 1 |
| Bjarnason, O | 1 |
| Riis, P | 1 |
| Dixon, AJ | 1 |
| Davies, J | 1 |
| Dormandy, TL | 1 |
| Hamilton, EB | 1 |
| Holt, PJ | 1 |
| Mason, RM | 1 |
| Thompson, M | 1 |
| Weber, JC | 1 |
| Zutshi, DW | 1 |
| Clarke, DN | 1 |
| Mowat, NA | 1 |
| Brunt, PW | 1 |
| Bain, LS | 1 |
| Strickland-Hodge, B | 1 |
| Thomas, TR | 1 |
| Gould, WA | 1 |
| Haslock, I | 1 |
| Paton, A | 1 |
| Howden, CW | 1 |
| Hernandez Avila, M | 1 |
| Walker, AM | 1 |
| Romieu, I | 1 |
| Spiegelman, DL | 1 |
| Perera, DR | 1 |
| Jick, H | 1 |
| McNeil, D | 1 |
| Piper, DW | 1 |
| Bernier, JJ | 1 |
| Florent, C | 1 |
| Murray, RM | 1 |
| Timbury, GC | 1 |
| Linton, AL | 1 |
| Lee, P | 1 |
| Ahola, SJ | 1 |
| Grennan, D | 1 |
| Brooks, P | 1 |
| Buchanan, WW | 1 |
| Hill, HF | 1 |
| Hill, AG | 2 |
| Mowat, AG | 1 |
| Ansell, BM | 1 |
| Mathews, JA | 1 |
| Seifert, MH | 1 |
| Gumpel, JM | 1 |
| Christie, GA | 1 |
| Chamberlain, MA | 1 |
| Chalmers, TM | 1 |
| Huskisson, EC | 1 |
| Hart, FD | 1 |
| Shenfield, GM | 1 |
| Taylor, RT | 1 |
| Pinals, RS | 1 |
| Christensen, JK | 1 |
| Fischer, PA | 1 |
| Jorgensen, TG | 1 |
| Strandbygaard, N | 1 |
| Duggan, JM | 1 |
| Edwards, FC | 1 |
| Coghill, NF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA)[NCT00441727] | Phase 3 | 2,426 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Self-Administered Hypnotherapy for Functional Dyspepsia[NCT03884270] | 23 participants (Actual) | Interventional | 2019-05-03 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 mg | 591 |
| Esomeprazole 20 mg | 577 |
| Placbo | 504 |
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 mg | 554 |
| Esomeproazole 20 mg | 537 |
| Placebo | 451 |
(NCT00441727)
Timeframe: The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 | 214 |
| Esomeproazole 20 | 213 |
| Placebo | 380 |
The occurrence of gastric ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 1.1 |
| Esomeproazole 20 | 0.75 |
| Placebo | 4.1 |
The occurrence of ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 1.35 |
| Esomeproazole 20 | 1 |
| Placebo | 6.58 |
The occurrence of duodenal ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 0.24 |
| Esomeproazole 20 | 0.25 |
| Placebo | 2.73 |
Feasibility will be calculated as the proportion of participants who complete the hypnotherapy treatment program in comparison to those who drop out before treatment is completed. (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Hypnotherapy | 22 |
The BSI is an 18-item self-report questionnaire with responses on a 5-point Likert scale, ranging from 0 (not bothered by a symptom at all) to 4 (extremely bothered). Three subscales are calculated (somatization, depression, and anxiety) and the subscales can be aggregated to calculate an overall global psychological distress score. The overall score and subscale scores are converted to T-scores (with a population mean of 50 and a standard deviation of 10). Higher T-scores indicate more psychological distress and T-scores ≥63 indicate clinically significant psychological distress. The BSI score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -9.22 |
The PAGI-SYM is a 20-item self-report measure of functional dyspepsia symptom severity. The scale consists of 6 subscales (heartburn/regurgitation, nausea/vomiting, postprandial fullness/early satiety, bloating, upper abdominal pain, and lower abdominal pain). Each item is measured by a 6-point Likert scale ranging from 0 (no complaints) to 5 (severe complaints). Subscale scores are calculated by taking the mean of the items in each subscale. The total score is calculated by taking the mean of the subscale scores. Total scores range from 0 to 5, with higher scores indicating worse symptoms. The PAGI-SYM total score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3-months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -0.82 |
The NDI-SF is a 10-item self-report disease specific quality of life questionnaire. The scale consists of 5 sub-scales (tension/anxiety, interference with daily activities, disruption to regular eating/drinking, knowledge towards/control over disease, interference with work/study). Each item is measured by a 5-point Likert scale ranging from 0 (not applicable) to 4 (extremely). Individual items are aggregated to obtain a total score ranging from 0 to 100 with higher scores indicating greater impairment in quality of life. The NDI-SF score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -9.65 |
The VSI is a 15-item self-report questionnaire with responses ranging from 1 (strongly agree) to 6 (strongly disagree). The raw VSI score ranges from 0 (severe anxiety) to 75 (no anxiety). The VSI score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | 10.39 |
At both baseline and end of treatment, patients will be asked to report the number of outpatient visits and procedures they have had within the last 3 months related to their functional dyspepsia symptoms (NCT03884270)
Timeframe: Baseline, 12 weeks
| Intervention | number of events (Median) | |||
|---|---|---|---|---|
| Number of outpatient visits at baseline | Number of outpatient visits at end of treatment | Number of procedures at baseline | Number of procedures at end of treatment | |
| Hypnotherapy | 2 | 1 | 2 | 1 |
At baseline and end of treatment, patients will be asked to report any medications they are taking related to their functional dyspepsia symptoms. (NCT03884270)
Timeframe: Baseline, 12 weeks
| Intervention | number of medications (Median) | |
|---|---|---|
| Medications taking at baseline | Medications taking at end of treatment | |
| Hypnotherapy | 1 | 1 |
"At the end of treatment, patients were asked an open-ended question to obtain feedback on their experience using the web-based platform for treatment. They were asked to rate their difficulty using the web platform on a 7-point scale from Extremely difficult to Extremely easy." (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Extremely easy | Moderately easy | Somewhat easy | Neutral | Somewhat difficult | Moderately difficult | Extremely difficult | |
| Hypnotherapy | 17 | 3 | 1 | 1 | 0 | 0 | 0 |
"Treatment satisfaction will be assessed with a single item at the end of treatment asking how satisfied they were overall with their assigned treatment (on a 7-point scale from Extremely dissatisfied to Extremely satisfied)" (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Extremely dissatisfied | Very dissatisfied | Somewhat dissatisfied | Neutral | Somewhat satisfied | Very satisfied | Extremely satisfied | |
| Hypnotherapy | 1 | 0 | 0 | 2 | 12 | 4 | 3 |
18 reviews available for aspirin and Indigestion
| Article | Year |
|---|---|
[Enteric-coated aspirin does not reduce the risk of gastrointestinal side effects].
Topics: Aspirin; Dyspepsia; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Risk Factors; Tablets, Ente | 2014 |
Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Common Cold; Double-Blind Me | 2011 |
Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold.
Topics: Acetaminophen; Aspirin; Common Cold; Dyspepsia; Fever; Gastrointestinal Tract; Humans; Ibuprofen; No | 2012 |
[Gastrointestinal complications of nonsteroidal anti-inflammatory drugs and low-dose aspirin].
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Cyclooxygenase Inhi | 2003 |
The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Humans; Omeprazole; Peptic Ul | 2003 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr | 2004 |
Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumat | 2005 |
Gastrointestinal injury from NSAID therapy. How to reduce the risk of complications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dyspepsia; Gastrointest | 2005 |
[Gastroenterology in the elderly].
Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2005 |
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2006 |
NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Drug Combinations; Dy | 2006 |
Strategies to reduce the GI risks of antiplatelet therapy.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2005 |
[The most common drugs considered harmful to the stomach, Clinical and endoscopic studies].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Aspirin; Dyspepsia; Fema | 1980 |
Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: consensus and controversy. Introduction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase 2; Cyclooxygenas | 2001 |
Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Cyclooxygenase I | 2001 |
The impact of nonsteroidal anti-inflammatory drug-induced gastropathy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Dyspepsia; Histamine H2 Antagon | 2001 |
Review of flufenamic acid in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diarrhea; Dyspep | 1966 |
Ibuprofen. A review.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials | 1971 |
15 trials available for aspirin and Indigestion
| Article | Year |
|---|---|
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; | 2014 |
The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Double-Blind Method; Drug The | 2015 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
Topics: Age Factors; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, | 2013 |
Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bleeding Time; Cross-Over Studies; Double-B | 2002 |
Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, Non- | 2005 |
The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase 2 Inhi | 2007 |
Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen.
Topics: Acetaminophen; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Dyspepsia; Female; Humans; | 1975 |
A comparison of a new slow release aspirin ("slow aspirin") with plain aspirin in the treatment of rheumatoid disease.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Delayed-Action Preparations; Double-Blind Method; Drug | 1977 |
Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Dys | 1974 |
A new form of aspirin--"Catalgix Forte". Its acceptability and effectiveness.
Topics: Analgesia; Arthritis; Arthritis, Rheumatoid; Aspirin; Bicarbonates; Chronic Disease; Clinical Trials | 1968 |
Review of flufenamic acid in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diarrhea; Dyspep | 1966 |
Clinical experience with Ibuprofen in the treatment of rheumatoid arthritis.
Topics: Albuminuria; Alkaline Phosphatase; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspa | 1969 |
Ibuprofen. A review.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials | 1971 |
Salicylates in the management of rheumatoid arthritis.
Topics: Aminobenzoates; Arthritis, Rheumatoid; Aspirin; Blood Coagulation; Buffers; Dyspepsia; Gastritis; Ga | 1971 |
41 other studies available for aspirin and Indigestion
| Article | Year |
|---|---|
Prevalence and sociodemographic determinants of dyspepsia in the general population of Rwanda.
Topics: Adult; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cos | 2020 |
Uninvestigated dyspepsia and associated factors of patients with gastrointestinal disorders in Dessie Referral Hospital, Northeast Ethiopia.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; | 2018 |
Comparison of incident dyspepsia between low-dose plain aspirin and enteric-coated aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Chemistry, Pharmaceutical; Dyspepsia; Humans; Incidence | 2010 |
Dyspepsia and aspirin.
Topics: Aspirin; Dyspepsia; Humans | 1947 |
Helicobacter pylori infection and administration of non-steroidal anti-inflammatory drugs down-regulate the expression of gastrokine-1 in gastric mucosa.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cyclooxygenase 2 Inhibitors; | 2012 |
Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Dyspepsia; Helicobacter | 2002 |
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barret | 2003 |
Evaluation of a model for counseling patients with dyspepsia in Swedish community pharmacies.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Community Pharmacy | 2003 |
[IS ASPIRIN A DANGEROUS DRUG?].
Topics: Anemia; Anemia, Hypochromic; Angioedema; Anticoagulants; Aspirin; Asthma; Blood Coagulation Disorder | 1963 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
Dyspeptic symptoms associated with Helicobacter pylori infection are influenced by strain and host specific factors.
Topics: Adult; Aged; Alcohol Drinking; Aspirin; Cohort Studies; Dyspepsia; Female; Helicobacter Infections; | 2004 |
The appropriate use of proton-pump inhibitor co-therapy with non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Cyclooxygenase Inhibitors; Drug | 2005 |
Definitions and classification of dyspepsia: pH, Helicobacter pylori, non-steroidal anti-inflammatory drugs--should we include gastro-oesophageal reflux disease?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Gastroesophageal Reflux; Helicobacter I | 2005 |
Itopride for functional dyspepsia.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzamides; Benzyl Compounds; D | 2006 |
[Gastroenterology in family practice. Updates for your "stomach patient"].
Topics: Anti-Ulcer Agents; Aspirin; Clopidogrel; Dyspepsia; Esophagitis, Peptic; Family Practice; Heartburn; | 2006 |
Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Dyspepsia; England; Epidemiologic | 2007 |
Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders.
Topics: Adult; Aged; Aspirin; Colonic Diseases, Functional; Comorbidity; Constipation; Cross-Sectional Studi | 2008 |
Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Dyspepsia | 2008 |
Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Female; Heartbu | 1995 |
Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups.
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Diseases, Functional; Dy | 1994 |
Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter pylori.
Topics: Adolescent; Adult; Alcohol Drinking; Analgesics; Antibodies, Bacterial; Aspirin; Blood Donors; Colon | 1994 |
[Use of acetylsalicylic acid and other antiphlogistics in hematemesis/melena].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Female; Hemate | 1994 |
Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups: lack of an association in a community.
Topics: Acetaminophen; Adult; Age Factors; Alcohol Drinking; Analgesics; Aspirin; Dyspepsia; Female; Humans; | 1994 |
Open access gastroscopy findings are unrelated to the use of aspirin and non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Esophagitis; Gastroscopy; | 1997 |
Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Donors; Dyspepsia; Female; Helicobact | 1998 |
Aspirin, myocardial infarction, and gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Gastrointestinal Hemorrhage; Humans; My | 1999 |
Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease.
Topics: Aspirin; Calcium Channel Blockers; Deglutition Disorders; Dyspepsia; Fibrinolytic Agents; Flatulence | 2001 |
Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Endoscopy, Digestive System; Fema | 2001 |
Costs of aspirin and statins in general practice.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug Costs; Dyspepsia; England; Family Practice; Female | 2002 |
A prospective comparative study of clinical and pathological characteristics in Icelandic and Danish patients with gastric ulcer, duodenal ulcer, and X-ray negative dyspepsia. II. Histological results.
Topics: Adult; Age Factors; Aged; Alcohol Drinking; Aspirin; Denmark; Duodenal Ulcer; Dyspepsia; Female; Gas | 1978 |
The effects of antacids on enteric-coated salicylate preparations.
Topics: Adult; Antacids; Arthritis, Rheumatoid; Aspirin; Dyspepsia; Female; Humans; Male; Middle Aged; Salic | 1976 |
Diseases of the alimentary system. Gastrointestinal reactions to drugs.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Aspirin; Constipation; Dyspepsia; Gastrointestinal D | 1976 |
Treatment of common minor ailments.
Topics: Acetaminophen; Antacids; Antiemetics; Aspirin; Dyspepsia; Female; Heartburn; Histamine H1 Antagonist | 1986 |
Choice of non-steroidal anti-inflammatory drug in persons treated for dyspepsia.
Topics: Acetaminophen; Aged; Aged, 80 and over; Analgesics; Antacids; Anti-Inflammatory Agents, Non-Steroida | 1988 |
Environmental factors and chronic unexplained dyspepsia. Association with acetaminophen but not other analgesics, alcohol, coffee, tea, or smoking.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Coffee | 1988 |
[Weakness of the gastric mucous barrier and hypersthenic dyspepsia].
Topics: Aspirin; Colonic Diseases; Dyspepsia; Gastric Mucosa; Gastroscopy; Humans; Membrane Potentials; Stom | 1985 |
Analgesic abuse in psychiatric patients.
Topics: Adult; Aged; Anemia; Aspirin; Creatinine; Dyspepsia; Female; Humans; Kidney Diseases; Male; Mental D | 1970 |
Observations on drug prescribing in rheumatoid arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Aspirin; Drug Prescriptions | 1974 |
[Psychiatric and gastroenterological evaluation of patients with duodenal ulcer confirmed at operation. 100 patients studied by preoperative psychiatric interview and enlarged histamine test with special reference to the relation between psychic factors a
Topics: Adolescent; Adult; Age Factors; Aged; Alcohol Drinking; Aspirin; Character; Child; Drinking Behavior | 1970 |
The relationship between perforated peptic ulcer and aspirin ingestion.
Topics: Aged; Aspirin; Duodenal Ulcer; Dyspepsia; Female; Humans; Male; Middle Aged; Peptic Ulcer Perforatio | 1965 |
Aetiological factors in chronic atrophic gastritis.
Topics: Adult; Aged; Alcoholic Beverages; Aspirin; Behavior; Biopsy; Blood Group Antigens; Drinking; Dyspeps | 1966 |